United States (US) Adalimumab Biosimilar Market (2025-2031) | Competitive Landscape, Analysis, Growth, Segmentation, Companies, Share, Industry, Value, Trends, Size & Revenue, Forecast, Outlook

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) Adalimumab Biosimilar Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) Adalimumab Biosimilar Market - Industry Life Cycle

3.4 United States (US) Adalimumab Biosimilar Market - Porter's Five Forces

3.5 United States (US) Adalimumab Biosimilar Market Revenues & Volume Share, By Product, 2021 & 2031F

3.6 United States (US) Adalimumab Biosimilar Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of autoimmune diseases in the US, leading to higher demand for adalimumab biosimilars.

4.2.2 Cost-effectiveness of adalimumab biosimilars compared to the reference product, driving adoption among healthcare providers and patients.

4.2.3 Favorable regulatory environment encouraging the development and approval of adalimumab biosimilars in the US market.

4.3 Market Restraints

4.3.1 Patent protections and intellectual property rights of reference adalimumab products limiting market entry and competition for biosimilar manufacturers.

4.3.2 Regulatory complexities and stringent approval processes for biosimilars, delaying market entry and commercialization.

4.3.3 Market resistance and skepticism among healthcare providers and patients towards biosimilars, impacting adoption rates.

6.1 United States (US) Adalimumab Biosimilar Market, By Product

6.1.1 Overview and Analysis

6.1.2 United States (US) Adalimumab Biosimilar Market Revenues & Volume, By Product, 2021- 2031F

6.1.3 United States (US) Adalimumab Biosimilar Market Revenues & Volume, By Exemptia, 2021- 2031F

6.1.4 United States (US) Adalimumab Biosimilar Market Revenues & Volume, By Adalirel, 2021- 2031F

6.1.5 United States (US) Adalimumab Biosimilar Market Revenues & Volume, By Cipleumab, 2021- 2031F

6.2 United States (US) Adalimumab Biosimilar Market, By Distribution Channel

6.2.1 Overview and Analysis

6.2.2 United States (US) Adalimumab Biosimilar Market Revenues & Volume, By Hospitals Pharmacies, 2021- 2031F

6.2.3 United States (US) Adalimumab Biosimilar Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F

7.1 United States (US) Adalimumab Biosimilar Market Export to Major Countries

7.2 United States (US) Adalimumab Biosimilar Market Imports from Major Countries

8.1 Average selling price (ASP) of adalimumab biosimilars compared to the reference product, indicating cost-effectiveness and market competitiveness.

8.2 Time to market approval for adalimumab biosimilars, reflecting regulatory efficiency and speed-to-market.

8.3 Patient and prescriber education initiatives uptake, measuring awareness and acceptance of adalimumab biosimilars in the US healthcare ecosystem.

9.1 United States (US) Adalimumab Biosimilar Market Opportunity Assessment, By Product, 2021 & 2031F

9.2 United States (US) Adalimumab Biosimilar Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F

10.1 United States (US) Adalimumab Biosimilar Market Revenue Share, By Companies, 2024

10.2 United States (US) Adalimumab Biosimilar Market Competitive Benchmarking, By Operating and Technical Parameters